Scott B Lovitch
Overview
Explore the profile of Scott B Lovitch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1728
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Williams J, Lucas F, Carrasco R, Lovitch S, Fisher D, Kupper T, et al.
J Cutan Pathol
. 2024 Jul;
51(10):777-782.
PMID: 38986680
Posttransplantation primary cutaneous T-cell lymphomas (PT-CTCL) are a rare complication of sustained immunosuppression in the posttransplant setting. When present, PT-CTCLs are typically EBV- and exhibit features of mycosis fungoides/Sézary syndrome...
2.
Sadigh S, DeAngelo D, Garcia J, Hasserjian R, Hergott C, Lane A, et al.
Mod Pathol
. 2023 Oct;
37(1):100352.
PMID: 37839675
In this study, we performed a comprehensive molecular analysis of paired skin and peripheral blood/bone marrow (BM) samples from 17 patients with cutaneous myeloid or cutaneous histiocytic-dendritic neoplasms. The cutaneous...
3.
Jambhekar A, Ackerman E, Alpay B, Lahav G, Lovitch S
medRxiv
. 2023 Sep;
PMID: 37732185
mutation predicts adverse prognosis in many cancers, including myeloid neoplasms, but the mechanisms by which specific mutations impact disease biology, and whether they differ between disease categories, remain unknown. We...
4.
AlJabban A, Paik H, Aster J, Berliner N, Brouillard J, Brown J, et al.
JCO Oncol Pract
. 2023 Sep;
20(2):220-227.
PMID: 37683132
Purpose: This study investigated the effectiveness of algorithmic testing in hematopathology at the Brigham and Women's Hospital and Dana-Farber Cancer Institute (DFCI). The algorithm was predicated on test selection after...
5.
Togami K, Chung S, Madan V, Booth C, Kenyon C, Cabal-Hierro L, et al.
Cancer Discov
. 2021 Oct;
12(2):522-541.
PMID: 34615655
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive leukemia of plasmacytoid dendritic cells (pDC). BPDCN occurs at least three times more frequently in men than in women, but the...
6.
Zee B, Poels K, Yao C, Kawabata K, Wu G, Duy C, et al.
iScience
. 2021 Jun;
24(6):102651.
PMID: 34151238
A hallmark of acute myeloid leukemia (AML) is the inability of self-renewing malignant cells to mature into a non-dividing terminally differentiated state. This differentiation block has been linked to dysregulation...
7.
Tsabar M, Lovitch S, Jambhekar A, Lahav G
Trends Cancer
. 2021 Jan;
7(4):301-308.
PMID: 33451930
Prediction of long-term outcomes from short-term measurements remains a fundamental challenge. Quantitative assessment of signaling dynamics, and the resulting transcriptomic and proteomic responses, has yielded fundamental insights into cellular outcomes....
8.
Tan C, Kuchroo J, Sage P, Liang D, Francisco L, Buck J, et al.
J Exp Med
. 2020 Oct;
218(1).
PMID: 33045061
Inhibitory signals through the PD-1 pathway regulate T cell activation, T cell tolerance, and T cell exhaustion. Studies of PD-1 function have focused primarily on effector T cells. Far less...
9.
Griffin G, Weirather J, Roemer M, Lipschitz M, Kelley A, Chen P, et al.
Blood
. 2020 Sep;
137(10):1353-1364.
PMID: 32871584
T-cell/histiocyte-rich large B-cell lymphoma (TCRLBCL) is an aggressive variant of diffuse large B-cell lymphoma (DLBCL) characterized by rare malignant B cells within a robust but ineffective immune cell infiltrate. The...
10.
Ouseph M, Hasserjian R, Dal Cin P, Lovitch S, Steensma D, Nardi V, et al.
Haematologica
. 2020 Mar;
106(2):555-564.
PMID: 32193254
Loss of the Y chromosome (LOY) is one of the most common somatic genomic alterations in hematopoietic cells in men. However, due to the high prevalence of LOY as the...